Guggenheim Capital’s BioLife Solutions BLFS Stock Holding History

Guggenheim Capital’s Portfolio BLFS Stock Details BLFS Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q4	–	Sell	-6,628	Closed	-$280K	–	2117
2021 Q3	$280K	Buy	+6,628	New	+$319K	﹤0.01%	1933

Other funds holding BLFS

Casdin Capital New York $1.32B AUM 76.62% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

FAM

Fred Alger Management New York $22.8B AUM 64.63% 1-Year Est. Return

GCM

Geneva Capital Management Milwaukee, Wisconsin $4.71B AUM 6.32% 1-Year Est. Return

Marshall Wace London, United Kingdom $100B AUM 35.1% 1-Year Est. Return

RIM

Ranger Investment Management Dallas, Texas $1.38B AUM 24.55% 1-Year Est. Return

Ameriprise Minneapolis, Minnesota $432B AUM 30.22% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Jennison Associates New York $145B AUM 34.61% 1-Year Est. Return

Guggenheim Capital's BLFS Position: Q4 2021 in Review

Guggenheim Capital sold out of BioLife Solutions (BLFS) in Q4 2021, closing a stake of 6,628 shares — an estimated $280K sold.

Guggenheim Capital first reported a position in BLFS in Q3 2021 and held it in 1 quarter. The position peaked at $280K in Q3 2021. 169 funds tracked by Wall St. Rank hold BLFS as of Q4 2021.

Guggenheim Capital reported no remaining BioLife Solutions position as of Q4 2021 after selling out during the quarter.
Guggenheim Capital sold 6,628 BioLife Solutions shares in Q4 2021, an estimated $280K.
Guggenheim Capital first reported a position in BioLife Solutions in Q3 2021 and held it in 1 quarter.
Guggenheim Capital's BioLife Solutions position peaked at $280K in Q3 2021.
169 funds tracked by Wall St. Rank held BioLife Solutions as of Q4 2021.

Based on Guggenheim Capital's 13F filing for Q4 2021, filed 14 Feb 2022.